血小板/淋巴细胞比值与PD-1/PD-L1抑制剂治疗非小细胞肺癌患者预后关系的Meta分析  

Association Between Platelet Lymphocyte Ratio and Prognosis of Non-small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Inhibitor:A Meta-analysis

作　　者：田甜[1] 唐苏丹 TIAN Tian;TANG Sudan(Department of Thoracic Oncology,West China Hospital of Sichuan University,Chengdu 610041,China;Department of Radiology,Yongchuan Hospital of Chongqing Medical University,Chongqing 402160,China)

机构地区：[1]四川大学华西医院胸部肿瘤科,成都610041 [2]重庆医科大学附属永川医院放射科,重庆402160

出　　处：《肿瘤防治研究》2021年第6期611-616,共6页Cancer Research on Prevention and Treatment

摘　　要：目的探讨血小板/淋巴细胞比值(PLR)在接受PD-1/PD-L1抑制剂治疗的非小细胞肺癌患者中的预后价值。方法检索PubMed、EMBASE、Web of Science、Medline、Cochrane Library、中国知网、中国生物医学文献数据库、维普、万方等数据库从建库至2020年4月公开发表的有关PLR与接受PD-1/PD-L1抑制剂治疗的非小细胞肺癌患者预后关系的文献。对纳入的文献进行质量评价,提取相关数据,采用Stata 15.0软件对风险比(HR)和95%CI进行Meta分析。结果共纳入6篇文献涉及551例患者。PLR升高与接受PD-1/PD-L1抑制剂治疗的非小细胞肺癌患者较差的OS、PFS相关。OS的亚组分析显示,高PLR在高加索人群、临界值≤169.05、依据以往文献制定PLR临界值以及多中心回顾性研究的患者中有预后价值(P<0.05)。PFS的亚组分析显示,高PLR在东亚人群、临界值≤169.05、依据以往文献制定PLR临界值以及单中心回顾性研究的患者中有预后价值(P<0.05)。结论在接受PD-1/PD-L1抑制剂治疗的NSCLC患者中,血液PLR升高与较差的OS和PFS相关,表明其可能作为NSCLC患者接受PD-1/PD-L1治疗潜在的生物预测标志物。Objective To investigate the prognostic value of the platelet-lymphocyte ratio(PLR)in nonsmall cell lung cancer patients treated with PD-1/PD-L1 inhibitors.Methods PubMed,EMBASE,Web of Science,Medline,Cochrane Library,China National Knowledge Infrastructure,Chinese Biomedical Literature Database,VIP,WanFang and other databases were searched online for eligible studies about evaluating the relation between PLR and the prognosis of NSCLC patients treated with PD-1/PD-L1 inhibitors from the establishment of database to April 2020.The relevant data of literatures that met the inclusion criteria were extracted.Pooled estimates of HR and 95%CI were calculated using Stata 15.0.Results We included six studies involving 551 patients.Elevated PLR was associated with worse OS and PFS of NSCLC patients treated with PD-1/PD-L1 inhibitors.The subgroup analysis of OS showed the prognostic value of high PLR in Caucasian race,cutoff value≤169.05,PLR cutoff value determination according to previous literature and multi-center retrospective study(P<0.05).Subgroup analysis of PFS showed the prognostic value of high PLR in East Asian race,cutoff value≤169.05,PLR cutoff value determination according to previous literature and single-center retrospective study(P<0.05).Conclusion Among NSCLC patients treated with PD-1/PD-L1 inhibitors,elevated blood PLR is associated with shorter OS and PFS,indicating that it may be a potential biomarker for PD-1/PD-L1 treatment on NSCLC patients.

关 键 词：肺肿瘤 血小板/淋巴细胞比值 META分析 总生存期 无进展生存时间 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]